Clinical Research Fellowship 2025 Cohort


Isla Leslie

Isla Leslie

Project title - Exploring the efficacy of a PARP inhibitor and Oncolytic virus and the effects on the immune microenvironment in triple negative breast cancer.

Why did you choose this project and how will it impact cancer patients? 

As a clinician I witnessed first-hand the transformative effects of immunotherapy on difficult to treat cancers, achieving the possibility of a "cure" for metastatic cancer. This inspired me to go into research to understand immune- tumour interactions further and test new immune-based therapies.

 

I hope that this will impact cancer patients by providing new treatments to patients who would not have had access to immunotherapy as well as expanding the use of oncolytic viruses which are an exciting treatment modality.

 


Interesting fact about yourself

I was the U16s Haggis eating champion.

 

 

 

 

David Hunt

David Hunt

Project title - Next Generation Prostate Radiotherapy: Pushing the Boundaries of Effective, Safe and Efficient Curative Treatment.

Why did you choose this project and how will it impact cancer patients? 

I chose this project to research how we can improve radiotherapy for men with prostate cancer, and train in precision MRI-adaptive radiotherapy. Prostate radiotherapy currently has good cure rates for localised disease, but can cause longstanding side-effects. 

 

I am investigating how we can increase the precision of prostate radiotherapy to try and reduce toxicity, and how we can broaden access to these treatments. I am working on the DESTINATION 2 trial, which is investigating 2-fraction tumour-focused radiotherapy. I am also researching how we can redesign radiotherapy preparation to make planning much faster and more efficient, which may be applicable within and beyond prostate radiotherapy.


Interesting fact about yourself

I have had a rowing boat named after me in Durham. 

 

 

 

Thurkaa Shanmugalingam

Thurkaa Shanmugalingam

Project title - Investigating the evolutionary dynamics of metastasis in invasive lobular breast cancer.

Why did you choose this project and how will it impact cancer patients? 

I chose this project because invasive lobular breast cancer (ILC) is a largely understudied subtype of breast cancer. These tumours tend to be more resistant to chemotherapy, which limits therapeutic options once they metastasise.

 

Additionally, ILC carries a greater risk of late recurrence and exhibits a unique pattern of metastasis, often spreading to areas like serosal surfaces, bone, omentum, ovaries, and leptomeninges; sites that are challenging to biopsy. By focusing on blood biopsies, which can capture circulating tumour cells and cell-free DNA, this approach offers a less invasive method for monitoring patients. It also provides valuable insights into the biology of metastatic disease and helps us investigate the mechanisms behind treatment resistance


Interesting fact about yourself

I learned Korean just to understand K-dramas! 

 

 

 

Luke Furtado O'Mahony

Luke Furtado O'Mahony

Project title - Developing a Novel 3D in vitro Model of the Tumour Microenvironment in High Grade Serous Carcinoma to Explore Immunotherapeutics such as Bispecific T-cell Engagers.

Why did you choose this project and how will it impact cancer patients? 

Many cancers such as lung cancer and melanoma have been revolutionised by immunotherapy, which forces the immune system to attack cancer cells. However, ovarian cancer has not seen the same benefit. My project is all about trying to make a model of ovarian cancer in the lab which might give us some insight into why this might be the case. If we can do this, our new understanding may lead to novel and effective ovarian cancer treatments for patients in the future.


Interesting fact about yourself

I go fishing semi-regularly and am a big fan of a sport called kendo - a form of Japanese fencing with bamboo sticks and metal helmets!